Cellular Regeneration: Resetting Your Body's Biological Clock
How breakthrough science is transforming aging from inevitable decline into optional biology
Loading immersive experience
/hero-video.mp4
Reversing
Biological Time
Through proprietary autologous cell technology that restores youthful function
Evidence-Based Medicine
Clinical Results That
Speak for Themselves
90%
Autoimmune symptom relief
67%
Osteoarthritis improvement
37
Alzheimer's patients treated
20B
Cells from 1cm² tissue
Our autologous rejuvenated fibroblast (auto-rFib) technology represents a breakthrough in regenerative medicine, achieving measurable improvements across multiple conditions through the power of your own cells.
The Journey to Renewal
Your Rejuvenation Process
From collection to results in six precise steps, each designed to ensure the highest quality and safety standards for your cellular therapy.
1
Tissue Collection
A small 1cm² skin biopsy is collected from behind the ear under local anesthesia
Learn more
2
Cell Isolation
Fibroblasts are isolated and expanded in our GMP-certified laboratories
Learn more
3
Rejuvenation Protocol
Proprietary 15-day treatment reverses cellular aging markers to embryonic levels
Learn more
4
Quality Validation
Single-cell RNA sequencing confirms successful rejuvenation before release
Learn more
5
Therapeutic Delivery
20 billion rejuvenated cells delivered via targeted injection or IV infusion
Learn more
6
Results & Monitoring
Extended telomeres and rejuvenated cellular markers confirmed through comprehensive testing
Learn more
Our complete rejuvenation process takes approximately 22 days from start to finish
The Science Behind
Our Success
Our breakthrough builds on Nobel Prize-winning research in cellular reprogramming, creating a new paradigm in regenerative medicine.
Epigenetic Reprogramming
Teaching old cells to remember their youthful state
100+ Peer-Reviewed Papers
Published in Cell, Nature, and Science journals
Multi-Pathway Approach
Immune modulation, growth factors, and tissue repair
9+ Patents Protected
Proprietary methods developed with UCLA
World-Class
Scientific Leadership
Our multidisciplinary team spans molecular biology, clinical medicine, finance, and biotechnology commercialization.
Diederik van der Reijt
CEO & Chairman
Serial biotech entrepreneur and investor
Dr. Yi Eve Sun
Professor, UCLA
Former Deputy Director of UCLA Stem Cell Biology
Dr. Lin Quan
Chief Scientist, IDDRC Center, UCLA
Clinical Director for preclinical research
Dr. Adeel Khan
Clinical Advisor, Regenerative Medicine
Board-certified physician and Co-founder of Minicircle
Dr. Joseph Regan
Non-Executive Director
Groundbreaking cancer stem cell pathway research
Jamie Grooms
Executive Board Member
CEO of NKore Biotherapeutics
Stephen Bradley
Non-Executive Director
Former British Consul-General to Hong Kong
Neil Bush
Senior Advisor
40+ years as global business leader
Dave Bizer
Senior Investment Advisor
Co-founder of GCW Global Customised Wealth
Rachid Bouzouba
Senior Capital Markets Advisor
Veteran financier with 30+ years' experience
Rogier van Bijnen
Legal Advisor
Asia-Pacific life sciences legal practice
Shirin Azad
Co-Founder
Author and investor in biotech talent and funding
Paul Spiegel
Strategic Advisor
International business development executive
Our research builds on foundational work in induced pluripotent stem cells, with 9+ proprietary patents protecting our breakthrough approaches.
Latest Updates
News & Research
Prometheus Cell Therapy: Mythical Regeneration Made Real
How autologous cellular reprogramming is transforming regenerative medicine from science fiction to clinical reality
Autologous Cell Therapy: Your Own Cells as Medicine
How Celljevity is revolutionizing regenerative medicine by transforming your own cells into powerful healing agents
Partner With Us to
Advance Human Longevity
Whether you're an investor, researcher, healthcare provider, or patient, join us in revolutionizing regenerative medicine.
Begin Your Journey to
Cellular Regeneration
Join pioneering institutions and individuals who are redefining the boundaries of human healthspan through autologous cell therapy.